Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
Jessica D. Sun(Threshold Pharmaceuticals (United States)), Charles P. Hart(University of Auckland), Deepthi Bhupathi(University of Auckland), Qian Liu(Sun Yat-sen University), Yan Wang(Shenzhen University), Wen‐Wu Li(Keele University), Ayesha S. Ruprell(Threshold Pharmaceuticals (United States)), Dharmendra Ahluwalia(Threshold Pharmaceuticals (United States)), Fanying Meng(Hunan University of Traditional Chinese Medicine)
Cited by 51
Related Papers
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
|Molecular Cancer Therapeutics|2011|206
DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
|Journal of Hematology & Oncology|2018|125
Ginsenoside Rg1 Protects against Oxidative Stress-induced Neuronal Apoptosis through Myosin IIA-actin Related Cytoskeletal Reorganization
|International Journal of Biological Sciences|2016|54
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
|Clinical Cancer Research|2019|53